JPMorgan Chase & Co. cut its stake in shares of Trinity Biotech PLC (NASDAQ:TRIB) by 49.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,200 shares of the company’s stock after selling 95,355 shares during the period. JPMorgan Chase & Co. owned approximately 0.44% of Trinity Biotech PLC worth $583,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TRIB. Renaissance Technologies LLC increased its position in shares of Trinity Biotech PLC by 21.1% during the first quarter. Renaissance Technologies LLC now owns 164,650 shares of the company’s stock valued at $981,000 after acquiring an additional 28,700 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Trinity Biotech PLC by 19.4% during the second quarter. Russell Investments Group Ltd. now owns 457,577 shares of the company’s stock valued at $2,745,000 after acquiring an additional 74,374 shares during the last quarter. Teton Advisors Inc. increased its position in shares of Trinity Biotech PLC by 0.3% during the second quarter. Teton Advisors Inc. now owns 231,730 shares of the company’s stock valued at $1,390,000 after acquiring an additional 800 shares during the last quarter. Lapides Asset Management LLC increased its position in shares of Trinity Biotech PLC by 0.4% during the second quarter. Lapides Asset Management LLC now owns 1,289,600 shares of the company’s stock valued at $7,738,000 after acquiring an additional 5,500 shares during the last quarter. Finally, Paradice Investment Management LLC increased its position in shares of Trinity Biotech PLC by 0.8% during the second quarter. Paradice Investment Management LLC now owns 1,639,296 shares of the company’s stock valued at $9,836,000 after acquiring an additional 12,800 shares during the last quarter. Institutional investors and hedge funds own 62.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Trinity Biotech PLC (TRIB) Holdings Decreased by JPMorgan Chase & Co.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/24/trinity-biotech-plc-trib-holdings-decreased-by-jpmorgan-chase-co.html.

Separately, Zacks Investment Research cut shares of Trinity Biotech PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, August 30th.

Shares of Trinity Biotech PLC (NASDAQ:TRIB) opened at 4.80 on Tuesday. The firm’s market capitalization is $104.87 million. Trinity Biotech PLC has a 12 month low of $4.79 and a 12 month high of $7.40. The firm’s 50 day moving average is $5.37 and its 200-day moving average is $5.58.

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Institutional Ownership by Quarter for Trinity Biotech PLC (NASDAQ:TRIB)

Receive News & Stock Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related stocks with our FREE daily email newsletter.